Amphastar Q3 revenue up 7% to $120.1M; GAAP EPS falls to $0.30 from $0.59 YoY

Amphastar Pharmaceuticals, Inc.

2022-Q3 EPS reported $1.09 revenue$363,964,000

Net revenues $120.1M for Q3 2022, up from $112.2M in Q3 2021 (7% growth).
GAAP diluted EPS $0.30 vs $0.59 prior year; adjusted non-GAAP EPS $0.38 vs $0.46.
Nine-month revenues $364.0M vs $316.9M; GAAP net income $57.5M vs $42.4M.
Growth cited from epinephrine, Primatene Mist, and glucagon sales.
No guidance issued; management optimistic about pipeline progress.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Amphastar Pharmaceuticals, Inc. reported three months ended September 30, 2022 results: revenue $120.1 million, net income $15.9 million, EPS $0.30 per share.

Period: three months ended September 30, 2022
Revenue: $120.1 million
Net income: $15.9 million
EPS: $0.30 per share
Result: reported results

Exact text from the filing

in such a filing. --- EX-99.1 (EX-99.1) --- Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 20 22 Reports Net Revenues of $120.1 Million for the Three Months Ended September 30, 2022 RANCHO CUCAMONGA, CA – November 7, 2022 – Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today

View on SEC.gov

Browse all earnings releases →

Amphastar Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001297184-22-000053

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.